Navigation Links
RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
Date:7/12/2013

owered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UCBs Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride
2. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
3. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
4. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
7. Vanda Pharmaceuticals, Inc. Sued by Investor
8. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
10. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
11. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... an intimidating job description: ensure products meet quality standards ... tight budgets and escalating regulations, quality leaders also have ... costs and risk. Those who don,t effectively ... quality function as well as marketplace failure and regulatory ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Week in Review: The Latest from PhRMA 2
... 17 Regado Biosciences, a privately held company leading the ... David J. Mazzo , PhD, President and CEO, will be presenting ... in Boston, Massachusetts . Dr. Mazzo,s presentation will be given ... in the Robinson Room and will include an overview of ...
... June 17 Salvin Dental Specialties, Inc. and LifeNet Health ... advance LifeNet Health,s OraGraft™ allograft products in the dental market. , ... The two companies ... the existing relationship between these two companies, which provides LifeNet Health ...
Cached Medicine Technology:Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 2Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 3LifeNet Health and Salvin Dental Specialties Announce Partnership 2LifeNet Health and Salvin Dental Specialties Announce Partnership 3
(Date:3/29/2015)... (PRWEB) March 30, 2015 Over 50 ... symptoms tied to undiagnosed autoimmune, thyroid, or hormone disorders. ... disorders, has personally treated hundreds of patients dealing with ... unaware of the treatment options for their ailments. Her ... solutions to women living with fatigue, brain fog, and ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 Adults ... that agencies promote nationally on the web can now ... permanent life insurance quotes can now be explored while ... http://quotespros.com/life-insurance.html . , Learning the differences between what a ... can be a challenge for some men and women. ...
(Date:3/29/2015)... March 29, 2015 The Contract ... trials and research, manage data results and help ... clients reach regulation standards. Contract research organizations (CROs) ... device manufacturing sectors. Industry operators provide clients with ... late-stage clinical research for Food and Drug Administration ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 Final ... new transition from Pixel Film Studios, entitled TranSports. ... made exclusively for Final Cut Pro X,” said Christiana ... users the tools needed to effortlessly transition using this ... TranSports, a new and uniquely styled transition pack for ...
(Date:3/28/2015)... Coffee could not only perk you up in ... disease, researchers have found. , They found that those who ... antioxidants. Antioxidants fight gum disease. Does coffee, then, help fight ... Henry M. Goldman School of Dental Medicine explored in a ... the Journal of Periodontology. , “This is the first long-term ...
Breaking Medicine News(10 mins):Health News:How to Turn Mid-life into the Good Life 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2
... new surgical approach to metabolic disease, may provide ... This data was presented today at the ... Meeting & Clinical Congress.(Logo: ... surgery," Chief of Gastrointestinal Metabolic Surgery at Weill ...
... China, the Netherlands Organization for Scientific Research and the ... with their Chinese counterparts regarding the theme for the ... round, the partners have selected the theme of "integrated ... level rise." , NWO and KNAW formulated the ...
... SAN DIEGO, May 14 Amylin Pharmaceuticals, Inc. (Nasdaq: ... in response to Carl Icahn:"Icahn Associates has been criticizing ... only fair to point out, according to Icahn,s own ... , "Icahn,s own performance elsewhere is well documented." About ...
... 14 John Hancock Long-Term Care (LTC) Insurance has ... services with more than 15 years of experience, to ... programs for its policyholders and their families. Beginning May ... as part of John Hancock,s individual and group LTC ...
... Conjugate Technology Used in Cimzia(R) Through Exclusive Nektar-UCB ... (Nasdaq: NKTR ) confirmed today UCB,s ... (FDA) has approved Cimzia(R) (certolizumab pegol), the only ... treatment of adult patients with moderately to severely ...
... Inc. (Nasdaq: TSTF ) , ... services, today announced that its travel nurse and allied ... agreement giving it the opportunity to provide temporary healthcare ... networks devoted exclusively to cancer treatment and research. ...
Cached Medicine News:Health News:Can New Surgery Revolutionize Diabetes Treatment? 2Health News:Can New Surgery Revolutionize Diabetes Treatment? 3Health News:China and the Netherlands join forces for research into water management 2Health News:Amylin Issues Statement Regarding Open Letter From Icahn 2Health News:John Hancock Selects CHCS Services to Manage Long-Term Care Insurance Provider Discount and Caregiver Programs 2Health News:John Hancock Selects CHCS Services to Manage Long-Term Care Insurance Provider Discount and Caregiver Programs 3Health News:John Hancock Selects CHCS Services to Manage Long-Term Care Insurance Provider Discount and Caregiver Programs 4Health News:Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 2Health News:Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 3Health News:TeamStaff Rx Signs Staffing Agreement With One of the Nation's Largest Healthcare Services Networks 2Health News:TeamStaff Rx Signs Staffing Agreement With One of the Nation's Largest Healthcare Services Networks 3
... a comprehensive pocket-sized reference to ... on the evaluation and management of diseases ... Updated annually. The complete content is available ... for Pocket PC- and Palm-based PDAs are ...
... The AT555 utilizes a patented hands-free ... your staff to take an accurate IOP ... slides the headrest to the left or ... their head against the comfortable headrest pad. ...
... The new Topcon KR-9000PW Wavefront Analyzer ... advanced and complete visual analysis system ... incorporates a full range auto refractometer, ... system, while adding the benefits of ...
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
Medicine Products: